for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Thermo Fisher Scientific Inc.

TMO.N

Latest Trade

463.08USD

Change

-0.39(-0.08%)

Volume

205,181

Today's Range

455.79

 - 

463.43

52 Week Range

324.88

 - 

532.52

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
463.47
Open
457.74
Volume
205,181
3M AVG Volume
36.87
Today's High
463.43
Today's Low
455.79
52 Week High
532.52
52 Week Low
324.88
Shares Out (MIL)
396.34
Market Cap (MIL)
184,108.80
Forward P/E
21.16
Dividend (Yield %)
0.22

Next Event

Thermo Fisher Scientific Inc Annual Shareholders Meeting

Latest Developments

More

Thermo Fisher Reports Q1 Earnings Of $5.88 Per Share

Thermo Fisher Scientific To Acquire PPD, Inc., A Leading Clinical Research Organization

Thermo Fisher Nears Deal To Buy PPD For More Than $15 Billion- WSJ

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Thermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. develops, manufactures and sells a range of products. The Company operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. It offers its products and services through various brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines. Analytical Instruments segment provides a broad offering of instruments, consumables, software and services that are used for a range of applications in the laboratory. Specialty Diagnostics segment offers a wide range of diagnostic test kits, reagents, culture media, instruments and associated products. Its Laboratory Products and Services segment offers products and solutions needed for the laboratory.

Industry

Medical Equipment & Supplies

Contact Info

168 3rd Ave

WALTHAM, MA

02451-7551

United States

+1.781.6221000

https://www.thermofisher.com/

Executive Leadership

Marc N. Casper

Chairman of the Board, President, Chief Executive Officer

Stephen Williamson

Chief Financial Officer, Senior Vice President

Mark Stevenson

Chief Operating Officer, Executive Vice President

Michel Lagarde

Executive Vice President

Michael A. Boxer

Senior Vice President, General Counsel

Key Stats

1.73 mean rating - 22 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

24.4K

2019

25.5K

2020

32.2K

2021(E)

35.8K
EPS (USD)

2018

11.120

2019

12.350

2020

19.550

2021(E)

22.144
Price To Earnings (TTM)
29.32
Price To Sales (TTM)
5.71
Price To Book (MRQ)
5.39
Price To Cash Flow (TTM)
21.16
Total Debt To Equity (MRQ)
62.99
LT Debt To Equity (MRQ)
55.37
Return on Investment (TTM)
11.49
Return on Equity (TTM)
10.01

Latest News

Latest News

Thermo Fisher profit beats estimates on COVID-19 vaccine demand surge

Thermo Fisher Scientific Inc beat first-quarter profit estimates on Thursday as strong sales of materials used to make COVID-19 vaccines and treatments helped offset slowing demand for tests that detect the novel coronavirus.

Thermo Fisher profit nearly triples on life sciences, COVID-19 test boost

Thermo Fisher Scientific Inc on Thursday posted quarterly profit that nearly tripled, helped by increased demand for its COVID-19 tests and a jump in sales at its life sciences unit.

Thermo Fisher expands pharma service business with $17.4 billion PPD acquisition

Medical device maker Thermo Fisher Scientific Inc said on Thursday it would acquire contract researcher PPD Inc for $17.4 billion as it looks to add more muscle to its pharmaceutical services business.

Cravath, Simpson, Arnold & Porter line up for Thermo Fisher's $17.4 bln PPD buy

Cravath, Swaine & Moore and Arnold & Porter Kaye Scholer are guiding medical device maker Thermo Fisher Scientific Inc in its $17.4 billion cash acquisition of drug testing company PPD Inc, which turned to Simpson, Thacher & Bartlett.

Thermo Fisher to buy PPD in $21 billion deal

Thermo Fisher Scientific Inc on Thursday said it would acquire contract research firm PPD Inc for about $20.9 billion, including net debt. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Bernard Orr)

Thermo Fisher in late talks to buy PPD for over $15 billion - WSJ

Medical device company Thermo Fisher Scientific is nearing a deal to buy contract research firm PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Thermo Fisher in late talks to buy PPD for over $15 bln - WSJ

Thermo Fisher Scientific is nearing a deal to buy PPD Inc for more than $15 billion, the Wall Street Journal reported on Wednesday, citing people familiar with the matter.

Thermo Fisher to work with Pfizer-BioNtech on vaccine production in Italy

Thermo Fisher Scientific said on Thursday it would work with Pfizer and BioNtech to produce their COVID-19 vaccine in Italy.

Belgian plant says it complies with AstraZeneca contract amid vaccine supply cuts

A plant in Belgium said to be the main cause of big cuts in AstraZeneca's COVID-19 vaccine supplies to the European Union said on Wednesday it had complied with all its obligations under a contract it has with the Anglo-Swedish firm.

Qiagen is interested in organic growth and acquisitions - CEO

Genetic testing specialist Qiagen's Chief Executive Thierry Bernard said the company is interested in organic growth and "bolt-on" acquisitions, when asked about recent merger and acquisition speculation during a results conference call on Wednesday.

Thermo Fisher sees 2021 profit above estimates on COVID-testing boost

Thermo Fisher Scientific Inc on Monday forecast 2021 profit above market estimates and posted better-than-expected quarterly earnings as it continues to gain from upbeat demand for its COVID-19 tests and materials for vaccine production.

Thermo Fisher sees 2021 profit above Street on COVID testing boost

Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, on Monday forecast 2021 profit above market estimates as it continues to gain from upbeat demand for its COVID-19 tests and materials for vaccine production.

Thermo Fisher buys Henogen for nearly $880 million in gene therapy expansion

Thermo Fisher Scientific Inc said on Friday it completed its 725 million euros ($879.72 million) acquisition of Belgium-based Henogen SA that will help strengthen the medical device maker's position in the fast-growing field of gene therapy manufacturing.

REFILE-Thermo Fisher buys Belgium's Henogen for nearly $880 mln

Medical device maker Thermo Fisher Scientific Inc said on Friday it has completed acquisition of Henogen SA, a Belgium-based viral vector manufacturing business, for about 725 million euros ($879.72 million) in cash.

Oxford ups COVID-19 testing capacity with Thermo Fisher deal

The University of Oxford has partnered with U.S.-based Thermo Fisher Scientific to ramp up its capacity to deliver COVID-19 testing data and help collect and quantify immune responses in its vaccine trials, the university said on Tuesday.

Inovio partners with Thermo Fisher to bolster COVID-19 vaccine supply

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture the drug developer's experimental coronavirus vaccine, as it looks to boost the supply ahead of large trials this month.

Inovio bolsters COVID-19 vaccine supply with Thermo Fisher deal

Inovio Pharmaceuticals Inc said on Tuesday that Thermo Fisher Scientific would manufacture its experimental coronavirus vaccine to boost the supply of the vaccine.

Qiagen chairman quits after Thermo Fisher's takeover bid fails

Qiagen <QIA.DE> said its non-executive Chairman Hakan Bjoerklund had resigned with immediate effect after the genetic testing company's shareholders rejected an improved takeover offer from Thermo Fisher <TMO.N>.

Thermo Fisher's Qiagen bid fails after target gets COVID testing boost

Thermo Fisher <TMO.N> has walked away from its takeover deal with Qiagen <QIA.DE> after the German genetic testing specialist's earnings were boosted by coronavirus diagnostics, leaving its shareholders reluctant to cash out.

Thermo Fisher ends deal agreement for genetic testing firm Qiagen

Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met. Thermo Fisher's revised offer had valued Qiagen at 11.3 billion euros ($13.38...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up